Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens.
about
A combination drug of abacavir-lamivudine-zidovudine (Trizivir®) for treating HIV infection and AIDSA combination drug of abacavir-lamivudine-zidovudine (Trizivir®) for treating HIV infection and AIDSMarkov Chain Modelling Analysis of HIV/AIDS Progression: A Race-based Forecast in the United States.A novel computerized functional assessment for human immunodeficiency virus-associated neurocognitive disorder.Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more."That is why I stopped the ART": patients' & providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme.Adherence support workers: a way to address human resource constraints in antiretroviral treatment programs in the public health setting in Zambia.Understanding the facilitators and barriers of antiretroviral adherence in Peru: a qualitative study.Who is accessing public-sector anti-retroviral treatment in the Free State, South Africa? An exploratory study of the first three years of programme implementationContrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort studyLongitudinal changes in regional fat content in HIV-infected children and adolescents.Provider-patient communication about adherence to anti-retroviral regimens differs by patient race and ethnicity.Magnitude and determinants of nonadherence and nonreadiness to highly active antiretroviral therapy among people living with HIV/AIDS in Northwest Ethiopia: a cross-sectional study.Anxiety and depression symptoms as risk factors for non-adherence to antiretroviral therapy in BrazilAssociations among correlates of schedule adherence to antiretroviral therapy (ART): a path analysis of a sample of crack cocaine using sexually active African-Americans with HIV infection.Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive statusPhysician estimate of antiretroviral adherence in India: poor correlation with patient self-report and viral load.Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS.Drug use and medication adherence among HIV-1 infected individuals.Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management.Functional consequences of HIV-associated neuropsychological impairmentMedication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity.HIV-transmission-related risk behavior in HIV+ African American men: Exploring biological, psychological, cognitive, and social factors.Validity of behavioral measures as proxies for HIV-related outcomesMedication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuseNon-adherence to anti-TB drugs among TB/HIV co-infected patients in Mbarara Hospital Uganda: prevalence and associated factors.The impact of illicit drug use and substance abuse treatment on adherence to HAART.Psychosocial burdens negatively impact HIV antiretroviral adherence in gay, bisexual, and other men who have sex with men aged 50 and olderPooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection.Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysisDisparities in outcomes for African American and Latino subjects in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial.The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials.The HIV Medication Taking Self-efficacy Scale: psychometric evaluation.Predictors of adherence to antiretroviral therapy among people living with HIV/AIDS in resource-limited setting of southwest ethiopia.A simple single-item rating scale to measure medication adherence: further evidence for convergent validityDepressive symptoms, lifestyle structure, and ART adherence among HIV-infected individuals: a longitudinal mediation analysis.Correlation between use of antiretroviral adherence devices by HIV-infected youth and plasma HIV RNA and self-reported adherenceValidating five questions of antiretroviral nonadherence in a public-sector treatment program in rural South AfricaAdherence to HAART among patients with HIV: breakthroughs and barriers.Clinic Attendance for Medication Refills and Medication Adherence amongst an Antiretroviral Treatment Cohort in Uganda: A Prospective Study.
P2860
Q24239831-C0F864F1-7A3D-4814-A5D2-56E4FC09F13BQ24246228-D03D830C-7E52-466D-BB72-74FC5979C7B1Q30362726-E24AB27C-96AE-4306-85DB-49AFC1A7CC90Q30548228-DB041E4D-FCA9-4684-B7AD-4134B49D6F40Q33262818-D6D359D2-E6F1-4984-93A8-D39A14BF21CFQ33320220-1104BEB8-5490-4F08-8CB3-06BFDB1D6BB2Q33336597-6D3E950D-3102-43D6-8398-52A523F8EC97Q33523621-396448C0-F0BD-411D-A644-FDF9DEF0EA17Q33622913-11DE5848-100D-4738-BD52-37588D64E07EQ33637867-01701D4E-27FC-4B62-89D1-2B9240FF24EBQ33693051-1C2C4EFB-816B-4D4B-9A20-78BB2FB5C4BAQ33717560-F5E095AC-70D8-4A60-9FC9-E047FC7790F8Q33753410-6AD3459F-CF2A-45AD-B32C-528B11207D11Q33809235-4769E10E-8F0E-4AD9-A9D4-A02E9D48DF0EQ33814884-C986D8C8-4F77-4016-B4D2-5696ADBCA82BQ33827543-16CD925E-6C77-4E11-8163-4EBC13BD359EQ33827782-225CE0E0-7336-4988-B252-D094F54DFAB1Q33834254-44F05202-AA73-422A-9284-858461D3F259Q33841530-4DCC0C9C-EC48-4362-8C4F-68F680951973Q33851716-CE7728E4-ACF0-4479-A796-5A4E2195AE7BQ33855943-5D88282C-99DF-41D4-A09A-6B074F184DA5Q33855976-5339D4A0-3EFF-47A2-944E-7605DD70EB36Q33902346-AD3D321C-378B-4F41-9793-0ACD52143D67Q33913873-FB772BAE-24C8-479A-8799-79C6A6773302Q33917628-C6C8C3ED-CC2D-4733-92A7-F17B1C6AFA93Q33935756-EED8E969-FA75-49F2-AB9C-AD50C3A5DCA3Q34019885-BC4962A6-27A9-471F-8AB9-3E48D038DC55Q34021581-5B12A61B-B613-4F90-9298-258FEE71D4DBQ34042986-484C16EC-492E-4BE1-A6B7-A3C7AA669059Q34103635-35954B9F-A4A5-431D-A598-BEA90691B199Q34104857-C9DEE5EB-D234-4A3B-89F6-5D230F8BF3F4Q34120588-E4ABC9DA-BB97-49A3-B3BF-A7BE57612E9FQ34268326-9C2D4951-44BA-4FC6-8BF9-CDA30C536C50Q34335232-A83F31F5-42A7-4627-BB8D-875FF9DE5896Q34462551-4D090C23-4A8B-43DE-93C2-6FC74E0AB2F2Q34588765-CD5CC064-4B34-484F-95A0-D213C83186FFQ34603715-6581B17B-5BF7-4BED-963F-C789BAA19A69Q34624904-C4C8B683-DD89-46C0-BC93-1CB48B0A321CQ34664263-E92635D3-7851-449F-A3DF-59803A399F8BQ34729754-616A5DB7-CDB8-4936-8A2D-5A4A7BDE94E1
P2860
Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Predictors of self-reported ad ...... idrug antiretroviral regimens.
@en
type
label
Predictors of self-reported ad ...... idrug antiretroviral regimens.
@en
prefLabel
Predictors of self-reported ad ...... idrug antiretroviral regimens.
@en
P2093
P1476
Predictors of self-reported ad ...... idrug antiretroviral regimens.
@en
P2093
Bormann JE
Bozzette SA
Gifford AL
Richman DD
Shively MJ
P304
P356
10.1097/00126334-200004150-00005
P407
P577
2000-04-01T00:00:00Z